Merck is making a $125 million investment in Moderna as part of a new funding round. "We're encourage by the potential for RNA-based vaccines," says Eric Rubin, a Merck vice president.
More From BioPortfolio on "Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer"